We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

116 hedge funds and large institutions have $1.38B invested in GW Pharmaceuticals Plc American Depositary Shares in 2016 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 22 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 22

35% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 23

34% more capital invested

Capital invested by funds: $1.03B → $1.38B (+$351M)

7% more funds holding

Funds holding: 108116 (+8)

6% more call options, than puts

Call options by funds: $113M | Put options by funds: $107M

Holders
116
Holders Change
+8
Holders Change %
+7.41%
% of All Funds
3.09%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
31
Increased
32
Reduced
22
Closed
23
Calls
$113M
Puts
$107M
Net Calls
+$6.33M
Net Calls Change
+$28.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of Montreal
101
Bank of Montreal
Ontario, Canada
$9K
AA
102
AlphaMark Advisors
Kentucky
$8K
DOA
103
D'Orazio & Associates
Virginia
$7K
Northwestern Mutual Wealth Management
104
Northwestern Mutual Wealth Management
Wisconsin
$7K +$2.27K +27 +54%
ASN
105
Advisory Services Network
Georgia
$6K -$6.14K -73 -53%
MSFP
106
Mark Sheptoff Financial Planning
Connecticut
$6K
CHC
107
City Holding Co
West Virginia
$5K
LWCFA
108
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$5K
ST
109
Smithfield Trust
Pennsylvania
$5K
WEC
110
Winslow Evans & Crocker
Massachusetts
$4.58K
KTC
111
Kistler-Tiffany Companies
Pennsylvania
$4K +$3.7K +44 New
HDIM
112
Hanson & Doremus Investment Management
Vermont
$3K
Acadian Asset Management
113
Acadian Asset Management
Massachusetts
$3K +$3.03K +36 New
BlackRock
114
BlackRock
New York
$2K
Point72 Asset Management
115
Point72 Asset Management
Connecticut
-$36.7M -508,143 Closed
O
116
OrbiMed
New York
-$13.8M -190,600 Closed
Renaissance Technologies
117
Renaissance Technologies
New York
-$12.9M -179,400 Closed
RG
118
Redmile Group
California
-$5.94M -82,300 Closed
Susquehanna International Group
119
Susquehanna International Group
Pennsylvania
-$4.88M -57,997 Closed
SM
120
Sabby Management
Florida
-$2.07M -24,603 Closed
NIT
121
NumerixS Investment Technologies
British Columbia, Canada
-$1.75M -24,300 Closed
HI
122
HBK Investments
Texas
-$1.39M -19,232 Closed
Jane Street
123
Jane Street
New York
-$1.52M -18,072 Closed
PA
124
Perceptive Advisors
New York
-$946K -13,109 Closed
TI
125
Trexquant Investment
Connecticut
-$912K -12,643 Closed

GWPH Hedge Fund Activity: Q2 2016 in Review

116 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q2 2016, worth a combined $1.38B — up 34% from $1.03B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new GWPH positions and 23 closed out — a net gain of 8 holders — while 32 added to existing stakes and 22 trimmed.

The largest buyer was Scopia Capital Management, opening a new position worth an estimated $124M. The largest seller was Millennium Management, cutting an estimated $40.2M.

  • 116 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q2 2016, up from 108 in Q1 2016.
  • Funds reported $1.38B of GW Pharmaceuticals Plc American Depositary Shares stock for Q2 2016, up 34% quarter-over-quarter.
  • 31 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q2 2016 and 23 closed out, a net change of +8 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q2 2016 was Scopia Capital Management, an estimated $124M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q2 2016 was Millennium Management, an estimated $40.2M sold.

Based on aggregated 13F filings for Q2 2016.